A detailed history of Susquehanna International Group, LLP transactions in Lyra Therapeutics, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 12,913 shares of LYRA stock, worth $2,582. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,913
Previous 35,160 63.27%
Holding current value
$2,582
Previous $9,000 66.67%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.24 - $0.34 $5,339 - $7,563
-22,247 Reduced 63.27%
12,913 $3,000
Q2 2024

Aug 15, 2024

SELL
$0.26 - $6.25 $80,122 - $1.93 Million
-308,162 Reduced 89.76%
35,160 $9,000
Q1 2024

May 07, 2024

BUY
$4.55 - $6.53 $381,772 - $547,906
83,906 Added 32.34%
343,322 $2.14 Million
Q4 2023

Feb 14, 2024

BUY
$2.82 - $5.24 $272,287 - $505,953
96,556 Added 59.29%
259,416 $1.36 Million
Q3 2023

Nov 14, 2023

BUY
$2.95 - $4.8 $445,376 - $724,680
150,975 Added 1270.3%
162,860 $636,000
Q2 2023

Aug 11, 2023

BUY
$1.98 - $4.33 $23,532 - $51,462
11,885 New
11,885 $48,000
Q4 2022

Feb 14, 2023

SELL
$2.44 - $5.42 $19,461 - $43,229
-7,976 Reduced 37.0%
13,582 $42,000
Q3 2022

Nov 14, 2022

BUY
$4.95 - $6.6 $106,712 - $142,282
21,558 New
21,558 $108,000
Q1 2022

May 16, 2022

SELL
$3.5 - $5.36 $39,200 - $60,032
-11,200 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$4.22 - $9.41 $19,812 - $44,179
-4,695 Reduced 29.54%
11,200 $49,000
Q3 2021

Nov 15, 2021

SELL
$6.06 - $9.43 $34,142 - $53,128
-5,634 Reduced 26.17%
15,895 $145,000
Q2 2021

Aug 11, 2021

BUY
$6.91 - $12.59 $148,765 - $271,050
21,529 New
21,529 $173,000

Others Institutions Holding LYRA

About Lyra Therapeutics, Inc.


  • Ticker LYRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,826,400
  • Market Cap $6.37M
  • Description
  • Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained...
More about LYRA
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.